Here, we show that increasing ISR signaling with HF, an orally available activator of GCN2 that has progressed to phase 2 clinical trials for various indications, reduced glucose intolerance, weight gain, insulin resistance, and serum insulin levels in DIO mice. The gene discussed is INS; the disease is Glucose intolerance.